The improved Finapres apparatus, known as the Finometer, measures finger blood pressure noninvasively on a beat-to-beat basis and gives waveform measurements similar to intra-arterial recordings. The Finometer measures brachial pressure and corrects for finger pressure accordingly. It also corrects for the hydrostatic height of the finger with respect to the heart level. The objective was to validate the Finometer according to the revised British Hypertension Society (BHS) protocol and the criteria of the Association for the Advancement of Medical Instrumentation (AAMI). We carried out a main validation test using a subject group of 102 black women, which was also divided into smaller groups, namely 24 hypertensives, 25 obese normotensive and 35 lean normotensive women. Finometer and mercury sphygmomanometer blood pressure (BP) measurements were taken early in the morning before breakfast, after the subjects stayed overnight in a research unit. Within the whole subject group, the Finometer satisfied the AAMI criteria for accuracy and achieved an overall A/B grading according to the BHS criteria. The sphygmomanometer measurements were 128 7 20/ 78 7 12 mmHg compared to 130 7 20/78 7 11 mmHg for the Finometer. The average differences between the mercury sphygmomanometer and Finometer readings for systolic and diastolic BP were, respectively, À1.83 7 6.8 and 0.88 7 7.5. Systolic readings of the Finometer device differed by less than 5 mmHg for 64%, by less than 10 mmHg for 86% and differed by less than 15 mmHg for 96% of all readings. A total of 63% of all diastolic readings of the Finometer by less than 5 mmHg, 85% by less than 10 mmHg and 94% of all readings differed by less than 15 mmHg. On the basis of these results, the Finometer device satisfied the validation criteria of AAMI and received an A/B grading according to the BHS protocol. It can therefore be recommended for measurements in the clinical set-up and for research purposes.
Introduction
The measurement of the arterial pressure waveform, at the finger with the Finapres (FINger Arterial PRESsure) (TNO, Amsterdam) that was introduced in the early 1980s, was welcomed as a long-awaited step forward in the continuous measurement of blood pressure (BP). 1 For a few decades, noninvasive finger arterial BP measurement (Finapres/ Portapres) has become an accepted technology, widely used in different areas of research, ranging from basic research, such as autonomic control of cardiovascular function, hypertension, pharmacology and psychophysiology, to use in the operating room, clinical practice, aero-and space research. [2] [3] [4] It has been shown that the vascular unloading technique of Penáz together with the Physiocal criteria of Wesseling provides reliable, noninvasive and continuous estimates of BP. [5] [6] [7] However, previous studies 7 have indicated that although the Finapres fulfilled the accuracy requirements for the mean and diastolic mean difference (+1.7 mmHg (s.d. 6.8) and; À1.0 mmHg (s.d. 5.9), respectively), the Finapres systolic BP measurements did not fulfil the criteria of the Association for the Advancement of Medical Instrumentation (AAMI) (+7.2 mmHg (s.d. 13.7)), which requires a mean difference less than 5 mmHg and a standard deviation smaller than 8 mmHg. 8 This systematic bias for Finapres systolic pressure was also demonstrated in other reports. Bos et al 9 found on the Finapres peripheral systolic pressure was 15.7 mmHg higher than the intrabrachial level, and Dorlas et al 10 reported Finapres systolic bias of 7 mmHg.
The Finometer, which is the successor of the Finapres, is a further development that compensates for the distortion of the pressure waveform along the arm artery. It measures the brachial pressure in a traditional way and corrects the finger pressure accordingly. The Finometer also corrects for the hydrostatic height of the finger with respect to the heart level 11 and it has upgraded filtering software. 12 It is unknown whether the systolic pressure measurement of the Finometer device will also indicate the bias as shown with the Finapres. The objective of this study was therefore to perform a clinical validation for the use of the Finometer device in a research setting according to the revised protocol of the British Hypertension Society (BHS) 13 and the criteria of AAMI. 8 A further objective was to compare this validity within three different groups of subjects, namely (1) hypertensive subjects, (2) normotensive, obese and (3) normotensive, lean subjects (because it is known that the visco-elastic behaviour of the arteries may be influenced during obese and hypertensive conditions 14 ) and to prove the accuracy of BP measurement with the Finometer at different levels of blood pressure. 15 
Methods

Participants
An availability sample of 102 black women from a governmental institution participated in the study. Since this institution employs mostly younger women, the mean age of this group was relatively low, namely 31.25 7 8.64 years. From the total sample of 102 subjects, subjects with specific characteristics were placed into three different groups: a group of 25 were selected who were obese (BMIX30 kg/m 2 ) and normotensive (BPo140/90 according to the World Health Organization (WHO) standards 16 ), a group of 24 who were hypertensive (BPX140/90 mmHg according to the WHO 16 ) and a lean (BMIo25 kg/m 2 ) normotensive group of 35 subjects. These three groups do not total to 102 subjects, because some of the subjects of the total group were not placed into any of these three groups, for example, if being normotensive, and not lean or obese, but overweight (BMI: 25-29.9 kg/m 2 ). Although the whole group of 102 subjects comply to the BHS protocol, which requires a group of 85 subjects, 13 the division of this group into three smaller groups was performed only to give an indication of the accuracy of the Finometer in these conditions. The characteristics of these four groups are shown in Table 1 .
The study has been approved by the Ethics Committee of the Potchefstroom University for Christian Higher Education and the study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki. All subjects gave informed consent.
Experimental procedure
In total, 10 subjects were to report at a metabolic ward facility (consisting of 10 single bedrooms, a living room and a kitchen) at 1800 in the evening. They were all introduced to the experimental set-up and Finometer apparatus. The purpose of the introduction to the Finometer was to minimize or eliminate anticipation stress. All subjects provided answers to a general health questionnaire. They received a light meal, which excluded caffeine and alcohol, and went to sleep before 2300. The purpose of these dietary restrictions was to ensure a good night's sleep and a stable, resting BP value the next morning. All Finometer recordings and mercury sphygmomanometer measurements were obtained from 0600 the next morning, after the overnight rest and before breakfast. Subjects were not permitted to walk around or have anything to eat or drink until all recordings were completed. Body mass and height measurements were also taken.
These anthropometric measurements were performed according to standard methods as described by Norton and Olds. 17 Maximum height was measured to the nearest 0.1 cm by means of a stadiometer with the head in the Frankfort plane. Body mass was measured to the nearest 0.1 kg by means of a calibrated electronic scale (Precision Health scale). During these measurements, the subject had to stand erect with the feet together and without volitionally contracting the gluteal muscles.
On the grounds of the BHS protocol, it was decided to use sequential BP measurements rather than simultaneous measurements in this study. 13, 18 The subject was awake and lying in the Fowler's position in a quiet single bedroom while the BP measurements were performed. All BP measurements were taken on the left arm of the subject to eliminate differences between BP of the two arms. 19 Firstly, a BP reading was taken using a singleheaded stethoscope and a table-model mercury sphygmomanometer (Model ALPK2). It was ensured that the cuff fitted each subject well. Systolic Immediately afterwards, while lying in the same position, a resting Finometer recording was performed. Each subject in turn was connected to the Finometer device and BP was recorded continuously for a period of at least 7 min. After a recording period of 2 min, the Finometer offers the option to perform a return-to-flow systolic calibration. This is an individual patient level adjustment which calibrates the upper-arm pressure of each specific subject with her finger pressure. Highest precision in BP readings is obtained only after this calibration. From the 7 min continuous BP recording of the Finometer, the mean systolic blood pressure (SBP) and diastolic blood pressure (DBP) were determined from the mean BP of the last 2 min of the recording.
Immediately after the Finometer measurement, BP was measured twice with the mercury sphygmomanometer. Because of possible anticipation stress and the 'white coat' effect on the first sphygmomanometer measurement, it was decided to use only the sphygmomanometer readings (mean of two measurements) obtained after the Finometer recording. Another reason for only using the last sphygmomanometer BP measurements was to reduce the time lapse between the Finometer and sphygmomanometer readings.
The two observers were qualified cardiovascular physiologists with experience in measuring BP with the auscultatory method.
Computation of cardiovascular data
The Finometer device computed all cardiovascular variables online and stored the data in result files on a hard disk. The Beatscope 1.1 software program integrates the subject's gender, age, body mass and weight, and these information were integrated further to obtain the SBP and DBP. 14 
Statistical analysis
All processed data were transferred to Microsoft Excel and further statistically analysed by means of the software computer package Statistica. 20 This program was mainly used to provide descriptive statistics and for drawing graphs.
Results
To give a representation of the range of BP, and to assess the agreement between the BP as measured by the mercury sphygmomanometer and Finometer, two plots as described by Bland and Altman 21 are presented in Figure 1 (SBP) and Figure 2 (DBP). The limits of agreement 21 (determined by: mean difference 7 2 Â s.d.) for the SBP data were 11.83 and À15.49 mmHg. For the DBP data, the limits of agreement were 15.87 and À14.09 mmHg. In both graphs, 93.14% of all differences lied between these limits of agreement. Of the 24 hypertensive subjects, five had isolated systolic hypertensive values. When focusing on the mean BP readings of the sphygmomanometer and Finometer, the highest recorded SBP was 230/108 mmHg and the highest DBP was 219/124 mmHg.
When focusing on the AAMI criteria (Table 2) , the results indicated that the mean differences (with standard deviations) between the Finometer and mercury sphygmomanometer in the whole subject group were À1.83 7 6.83 mmHg for SBP and 0.88 7 7.49 mmHg for DBP. It therefore satisfied the AAMI criteria, namely a mean difference less than 5 mmHg and a standard deviation smaller than 8 mmHg 8 ( Table 2) . The values obtained in the obese and hypertensive groups also comply to these criteria, whereas the standard deviation of the DBP in the lean, normotensive group exceeded the 8 mmHg by 0.63 mmHg.
When focusing on the BHS criteria within the whole group of 102 subjects, the absolute Validation of the Finometer AE Schutte et al differences between the standard mercury sphygmomanometer and the Finometer device were within an A/B grading range of the revised BHS protocol 13, 22 (Table 3) . For the whole group, the percentages of readings for all SBP and DBP differences were according to the BHS requirements, except that 94.1% of diastolic readings in the p15 mmHg mercury standard did not comply to the required 95%.
In the hypertensive group (N ¼ 24), the absolute differences in all three mercury standards (p5 mmHg, p10 mmHg, p15 mmHg) of SBP and DBP were greater than the required Grade A percentages (Table 3) , except for the SBP in the p5 mmHg range and DBP in the p15 mmHg range. In the normotensive, obese group (N ¼ 25), all differences were greater than the required Grade A percentages, except for the DBP in the p10 mmHg range. In the lean, normotensive group (N ¼ 35), all the SBP percentages acquired an A grading and all DBP percentages acquired a B grading. All percentages indicated in Table 3 have therefore obtained either an A or B grading, and no percentage acquired a C or D.
Discussion
The present study was performed to validate the improved Finapres, namely the Finometer, which is a device that measures BP noninvasively on a beatto-beat basis similar to intra-arterial recordings. On the basis of the results obtained in this study, the Finometer device satisfied the validation criteria of the BHS and AAMI within a group of 102 subjects, and obtained an A/B grading.
The groups of hypertensive, obese and normotensive lean subjects were much smaller than that recommended by the BHS and AAMI. Although the BHS and AAMI criteria (Tables 2 and 3) were met within the three groups, the small subject groups were a restriction of this study and the results can only be used as possible indications. Further studies are needed to validate the use of the Finometer within these circumstances and by making use of other population groups. The results indicate that the Finometer readings might also be valid when used in these groups. Despite the decreased viscoelastic behaviour in the hypertensive and obese subjects, the Finometer still indicated to be accurate. Previous validation of the Finometer's predecessor, the Finapres, stated that the Finapres systolic pressure may indicate quite large differences to the systolic pressure recorded more proximally in the circulation. 7 From the results of this study, the SBP difference in standard deviation was actually smaller than that of the DBP (Table 2) , and both SBP and DBP complied to AAMI criteria. This indicates that the Finometer's compensation for the distortion of the pressure waveform along the arm artery, correction for the finger pressure by using brachial pressure, upgraded software and correction for the hydrostatic height of the finger 11 might prove to have increased the Finometer's accuracy in measuring SBP.
Clinical blood pressure measurement almost exclusively uses noninvasive intermittent techniques such as the auscultatory (Riva-Rocci/Korotkoff) and oscillometric method which only provide a momentary value. Accuracy could easily be hampered by phenomena such as cuff response and 'white coat' hypertension. 23 The recent development of the Finometer's continuous noninvasive method provides new perspectives for medical practice and research possibilities, especially in areas in which beat-to-beat recording of the full BP curve is needed to obtain further insight into the dynamics of the cardiovascular system, 22 such as total peripheral resistance, cardiac output and arterial compliance. Since the results of this study have shown that the Finometer with its return-to-flow calibration and height correction does provide reliable BP values (BHS: Grade A/B), it is concluded that it might be recommended for use in a research setting and medical practice.
